Current understanding of synergistic interplay of chitosan nanoparticles and anticancer drugs: merits and challenges
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605504415 | ||
| 003 | CHVBK | ||
| 005 | 20210128100616.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150301xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00253-015-6384-9 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00253-015-6384-9 | ||
| 245 | 0 | 0 | |a Current understanding of synergistic interplay of chitosan nanoparticles and anticancer drugs: merits and challenges |h [Elektronische Daten] |c [Prameela Kandra, Hemalatha Kalangi] |
| 520 | 3 | |a Recent advances have been made in cancer chemotherapy through the development of conjugates for anticancer drugs. Many drugs have problems of poor stability, water insolubility, low selectivity, high toxicity, and side effects. Most of the chitosan nanoparticles showed to be good drug carriers because of their biocompatibility, biodegradability, and it can be readily modified. The anticancer drug with chitosan nanoparticles displays efficient anticancer effects with a decrease in the adverse effects of the original drug due to the predominant distribution into the tumor site and a gradual release of free drug from the conjugate which enhances drug solubility, stability, and efficiency. In this review, we discuss wider applications of numerous modified chitosan nanoparticles against different tumors and also focusing on the administration of anticancer drugs through various routes. We propose the interaction between nanosized drug carrier and tumor tissue to understand the synergistic interplay. Finally, we elaborate merits of drug delivery system at the tumor site, with emphasizing future challenges in cancer chemotherapy. | |
| 540 | |a Springer-Verlag Berlin Heidelberg, 2015 | ||
| 690 | 7 | |a Chitosan nanoparticles |2 nationallicence | |
| 690 | 7 | |a Biocompatibility |2 nationallicence | |
| 690 | 7 | |a Biomedical |2 nationallicence | |
| 690 | 7 | |a Anticancer drug |2 nationallicence | |
| 690 | 7 | |a Synergy |2 nationallicence | |
| 700 | 1 | |a Kandra |D Prameela |u Department of Biotechnology, GITAM Institute of Technology, GITAM University, 530045, Visakhapatnam, Andhra Pradesh, India |4 aut | |
| 700 | 1 | |a Kalangi |D Hemalatha |u Department of Biochemistry, Andhra University, 530003, Visakhapatnam, Andhra Pradesh, India |4 aut | |
| 773 | 0 | |t Applied Microbiology and Biotechnology |d Springer Berlin Heidelberg |g 99/5(2015-03-01), 2055-2064 |x 0175-7598 |q 99:5<2055 |1 2015 |2 99 |o 253 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00253-015-6384-9 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a review-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00253-015-6384-9 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kandra |D Prameela |u Department of Biotechnology, GITAM Institute of Technology, GITAM University, 530045, Visakhapatnam, Andhra Pradesh, India |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kalangi |D Hemalatha |u Department of Biochemistry, Andhra University, 530003, Visakhapatnam, Andhra Pradesh, India |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Applied Microbiology and Biotechnology |d Springer Berlin Heidelberg |g 99/5(2015-03-01), 2055-2064 |x 0175-7598 |q 99:5<2055 |1 2015 |2 99 |o 253 | ||